Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold Pharmaceutical has received orphan drug designation for TH-302, a cancer drug, from the US FDA.
Subscribe to our email newsletter
Threshold is presently testing TH-302 along with a commonly used chemotherapeutic agent, doxorubicin, in a late-stage trial to treat soft tissue sarcoma.
The orphan status can provide a seven-year marketing exclusivity for the drug from the date of approval.
The experimental drug had received orphan status from European health regulators.
Threshold chief executive Barry Selick said: "The results of our Phase 2 study (TH-CR-403) in soft tissue sarcoma are certainly supportive of a pivotal trial underway in this difficult to treat cancer."